Technology
Health
Biotechnology

Achieve Life Sciences

$3.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (6.71%) Today
-$0.02 (-0.66%) After Hours

Why Robinhood?

You can buy or sell ACHV and other stocks, options, ETFs, and crypto commission-free!

About

Achieve Life Sciences, Inc. Common Shares, also called Achieve Life Sciences, is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Read More Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Employees
13
Headquarters
Vancouver, British Columbia
Founded
1991
Market Cap
19.02M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
943.39K
High Today
$3.14
Low Today
$2.78
Open Price
$2.86
Volume
152.49K
52 Week High
$14.60
52 Week Low
$1.04

Collections

Technology
Health
Biotechnology
Pharmaceutical
Research And Development
Canada
North America

News

Markets InsiderMar 18

Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019

SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time. A live webcast of the presentation can be accessed at http...

644
Markets InsiderMar 14

Achieve Life Sciences Is All Fired Up - Stock Soars Over 70%

(RTTNews) - Shares of Achieve Life Sciences Inc. (ACHV) jumped over 70% in extended trading on Thursday as investors bet on the Company's Cytisinicline program, which is under development for smoking cessation. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfa...

1,289
PR NewswireMar 14

Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update

SEATTLE and VANCOUVER, British Columbia, March 14, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. Recent Highlights Completion of enrollment in 254-subject Phase 2b ORCA-1 trial of cytisinicline in U.S. smokers O...

186

Earnings

-$1.82
-$1.29
-$0.77
-$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.64 per share
Actual
-$0.55 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.